|
|
Volumn 30, Issue 2, 2012, Pages 217-
|
|
Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ARSENIC TRIOXIDE;
CYTARABINE;
RETINOIC ACID;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL PRACTICE;
CLINICAL TRIAL (TOPIC);
GOVERNMENT;
HEALTH CARE COST;
HUMAN;
IRAN;
LETTER;
MEDICAL ETHICS;
MONOTHERAPY;
PRIORITY JOURNAL;
PROMYELOCYTIC LEUKEMIA;
SCIENTIFIC MISCONDUCT;
ANTINEOPLASTIC AGENTS;
ARSENICALS;
FEMALE;
HUMANS;
LEUKEMIA, PROMYELOCYTIC, ACUTE;
MALE;
OXIDES;
|
|
EID: 84855567767
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2011.38.7654 Document Type: Letter |
|
Times cited : (9)
|
|
References (3)
|
